Table 2.
Mechanism of atopic dermatitis pathogenesis within proteomic analysis.
| Type of disease | Sample | Highlighting mechanism | Depth mechanism | Ref. |
|---|---|---|---|---|
| AD | Human [AD (n = 12), HCs (n = 13)] | Localization, regulation of biological quality, platelet activation, etc. | — | Chang et al. (2021) |
| AD | Human [AA (n = 35), HCs (n = 36), psoriasis (n = 19), AD (n = 49)] | Atherosclerosis signaling, immune pathways, cardiovascular pathway | — | Glickman et al. (2021) |
| AD | Human [AD (n = 4), HCs (n = 7), spontaneously healed AD (n = 4)] | — | — | Rindler et al. (2021) |
| AD | Human [AD (n = 34), HCs (n = 20)] | — | Insufficiency of IL-37 leads to dysregulation of serum protein and skin disruption in AD | Hou et al. (2021) |
| AD | Human [AD (n = 8), HCs (n = 8)] | Biological regulation, cellular component organization, etc. | — | Morelli et al. (2021) |
| AD | Human [AD (n = 20), HCs (n = 28)] | — | — | Pavel et al. (2020) |
| AD | Skin suction blisters and skin | — | — | Rojahn et al. (2020) |
| AD | Human [18–40 years old (n = 26), 41–60 years (n = 24),>60 years (n = 21), HCs (n = 37)] | Th1/Th2 differentiation, IL-4-mediated signaling, IL-5-mediated signaling, etc. | — | He et al. (2020) |
| AD | Human [AD + FA (n = 21), AD (n = 19), HCs (n = 22)] | Inflammatory response, glycolysis, oxidative stress response | — | Goleva et al. (2020) |
| AD | Human [AD (n = 20), HCs (n = 7)] | — | — | Umayahara et al. (2020) |
| ACD | Mice TGs | Response to stimulus, metabolic process, immune system process, etc. | — | Su et al. (2020) |
| AD | Human [AD (n = 76), HCs (n = 39)] | — | — | Leonard et al. (2020) |
| AD | Human | — | — | Yin et al. (2019) |
| AD | Human [AD pediatric (n = 30), healthy pediatric (n = 19), AD adult (n = 58), healthy adult (n = 18)] | — | — | Brunner et al. (2019) |
| AD | Human [HCs (n = 84),severe AD (n = 50), moderate AD (n = 123)] | — | — | Mikus et al. (2019) |
| AD | Human [HC (n = 10), AD (n = 20), CD (n = 10), AD and CD (n = 10), psoriasis (n = 12)] | — | — | Wang et al. (2017) |
| AD | Human [psoriasis (n = 22), AD (n = 59), HCs (n = 18)] | — | — | Brunner et al. (2017) |
| ACD | Dendritic-like cell line | Cell signaling, transcriptional regulation, protein transport, ubiquitination, etc. | MLK is one of FITC targets leading the specific protein haptenation and the subsequent pathway of dermal dendritic cells activation | Guedes et al. (2017) |
| AD | Spleen and thymus Treg cells | — | — | Lee et al. (2016) |
| AD | AD-NC/Nga mice | — | — | Kawasaki et al. (2014) |
| AD | Human [EH− (n = 18), EH+ (n = 17), non-atopic controls (n = 6)] | Skin barrier, generation of natural moisturizing factor | — | Broccardo et al. (2011) |
| AD | Human [AD (n = 8), HCs] | — | — | Kim et al. (2008) |
| AD | Human [ADe (n = 14), ADi (n = 10), HCs (n = 14)] | — | — | Park et al. (2007) |
| AD | Human [ADe (n = 14), ADi (n = 10), HCs (n = 14)] | — | — | Park et al. (2007) |
| AD | Human [ADe, ADi, HCs] | — | — | Park et al. (2006) |
| AD | Human [ADe, ADi, HCs] | — | — | Park et al. (2004) |
AD, atopic dermatitis; ACD, atopic contact dermatitis; HCs, human controls; AA, alopecia areata; TGs, trigeminal ganglions; CD, contact dermatitis; EH, eczema herpeticum; ADe, extrinsic AD; ADi, intrinsic AD; PsA, psoriatic arthritis; FITC, fluorescein isothiocyanate; MLK, mixed-lineage protein kinase.